N,Title,Authors,Journal,Date,Team,Url 1,"Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants.","Chauvin C, Levillayer L, Roumier M, Nielly H, Roth C, Karnam A, Bonam SR, Bourgarit A, Dubost C, Bousquet A, Le Burel S, Mestiri R, Sene D, Galland J, Vasse M, Groh M, Le Marchand M, Vassord-Dang C, Gautier JF, Pham-Thi N, Verny C, Pitard B, Planchais C, Mouquet H, Paul R, Simon-Loriere E, Bayry J, Gilardin L, Sakuntabhai A,",iScience,'2023-02-03,"Humoral Immunology, Ecology and Emergence of Arthropod-borne Pathogens, UMR2000 – Evolutionary genomics, modeling and health, Evolutionary genomics of RNA viruses",https://research.pasteur.fr/en/publication/tocilizumab-treated-convalescent-covid-19-patients-retain-the-cross-neutralization-potential-against-sars-cov-2-variants/